Market research
NG9.F NeoGenomics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 56.8
- Dividend yield
- Not available
- Beta
- 1.75
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US64049M2098
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 56.8
- Dividend yield
- Not available
- Beta
- 1.75
About
About NeoGenomics, Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NG9.F discussion.
5 years, 5 months ago
NeoGenomics, Inc is currently in a long term downtrend where the price is trading 2.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.1.
NeoGenomics, Inc's total revenue rose by 17.9% to $126M since the same quarter in the previous year.
Its net income has increased by 144.9% to $15M since the same quarter in the previous year.
Finally, its free cash flow fell by 103.2% to $-6M since the same quarter in the previous year.
Based on the above factors, NeoGenomics, Inc gets an overall score of 3/5.